Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa study of oral LAT8881 in neuropathic pain
2018-004534-15Phase 2Completed
- Sponsor
- Lateral Pharma
- Start
- Jul 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2 trial of LAT8881 in Neuralgia, postherpetic neuralgia (PHN) and diabetic polyneuropathy (DPN) (2 arms), sponsored by Lateral Pharma. Started Jul 2019; status: completed.
02
Drugs
LAT8881
03
Conditions
Neuralgiapostherpetic neuralgia (PHN)diabetic polyneuropathy (DPN)
Beyond the preview
Go deeper on 2018-004534-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004534-15.